Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

New data show DecisionDx-UM combined with PRAME provides superior prediction of metastasis and survival in uveal melanoma compared to NGS.